Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions

Nobuko Hijiya; Frederic Millot; Meinolf Suttorp

doi:10.1016/j.pcl.2014.09.008

Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions

Nobuko Hijiya^*, Frederic Millot, Meinolf Suttorp

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Review article › peer-review

59 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a rare disease in children. There is little evidence of biological differences between CML in children and adults, although host factors are different. Children develop distinct morbidities related to the off-target effects of tyrosine kinase inhibitors. The goal of treatment in children should be cure rather than suppression of disease, which can be the treatment goal for many older adults. This article reviews data from the literature on the treatment of CML, discusses the issues that are unique to CML in children, and recommends management that takes these issues into consideration.

Original language	English (US)
Pages (from-to)	107-119
Number of pages	13
Journal	Pediatric Clinics of North America
Volume	62
Issue number	1
DOIs	https://doi.org/10.1016/j.pcl.2014.09.008
State	Published - Feb 1 2015

Keywords

BCR-ABL1
Chronic myeloid leukemia
Hematopoietic stem cell transplant
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/j.pcl.2014.09.008

Cite this

@article{250eb7645d6540a8a0763ec2639b5981,

title = "Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions",

abstract = "Chronic myelogenous leukemia (CML) is a rare disease in children. There is little evidence of biological differences between CML in children and adults, although host factors are different. Children develop distinct morbidities related to the off-target effects of tyrosine kinase inhibitors. The goal of treatment in children should be cure rather than suppression of disease, which can be the treatment goal for many older adults. This article reviews data from the literature on the treatment of CML, discusses the issues that are unique to CML in children, and recommends management that takes these issues into consideration.",

keywords = "BCR-ABL1, Chronic myeloid leukemia, Hematopoietic stem cell transplant, Tyrosine kinase inhibitor",

author = "Nobuko Hijiya and Frederic Millot and Meinolf Suttorp",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.pcl.2014.09.008",

language = "English (US)",

volume = "62",

pages = "107--119",

journal = "Pediatric Clinics of North America",

issn = "0031-3955",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Chronic myeloid leukemia in children

T2 - Clinical findings, management, and unanswered questions

AU - Hijiya, Nobuko

AU - Millot, Frederic

AU - Suttorp, Meinolf

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Chronic myelogenous leukemia (CML) is a rare disease in children. There is little evidence of biological differences between CML in children and adults, although host factors are different. Children develop distinct morbidities related to the off-target effects of tyrosine kinase inhibitors. The goal of treatment in children should be cure rather than suppression of disease, which can be the treatment goal for many older adults. This article reviews data from the literature on the treatment of CML, discusses the issues that are unique to CML in children, and recommends management that takes these issues into consideration.

AB - Chronic myelogenous leukemia (CML) is a rare disease in children. There is little evidence of biological differences between CML in children and adults, although host factors are different. Children develop distinct morbidities related to the off-target effects of tyrosine kinase inhibitors. The goal of treatment in children should be cure rather than suppression of disease, which can be the treatment goal for many older adults. This article reviews data from the literature on the treatment of CML, discusses the issues that are unique to CML in children, and recommends management that takes these issues into consideration.

KW - BCR-ABL1

KW - Chronic myeloid leukemia

KW - Hematopoietic stem cell transplant

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84915758765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915758765&partnerID=8YFLogxK

U2 - 10.1016/j.pcl.2014.09.008

DO - 10.1016/j.pcl.2014.09.008

M3 - Review article

C2 - 25435115

AN - SCOPUS:84915758765

SN - 0031-3955

VL - 62

SP - 107

EP - 119

JO - Pediatric Clinics of North America

JF - Pediatric Clinics of North America

IS - 1

ER -

Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this